BACKGROUND: Orthopedic patients are at risk for adverse postoperative cardiovascular outcomes. QUESTIONS/PURPOSES: This pilot randomized controlled trial (RCT) of atorvastatin vs. placebo in orthopedic surgery patients was performed in order to assess: (1) the prevalence of perioperative myocardial injury; (2) the effect of atorvastatin on perioperative inflammation; and (3) the feasibility of performing a large RCT of statin therapy in orthopedic patients. METHODS: Hip fracture (hip Fx) and total hip and knee replacement (THR and TKR) patients were randomized 1:1 to atorvastatin 40 mg daily vs. placebo, starting preoperatively and continuing until postoperative day (POD) 45. High-sensitivity cardiac troponin I (hs-cTnI), high-sensitivity C-reactive protein (hs-CRP), and interleukin-6 (IL-6) were measured preoperatively and on POD 2. Patients were monitored for adverse events until POD 90. RESULTS: Five hundred fifty-six patients were screened, 22 were recruited (4 hip Fx, 11 THR, 7 TKR), and 2 withdrew. Most (80%) had detectable hs-cTnI (> 1.1 pg/mL) preoperatively. Twenty percent had a perioperative rise in hs-cTnI (≥ 10 pg/mL), which was not blunted by atorvastatin. Hs-CRP rose in 19/20 patients, and IL-6 rose in all patients. However, atorvastatin did not blunt the rise in these inflammatory biomarkers. On POD 2, IL-6 and hs-cTnI levels correlated (ρ = 0.59, p = 0.02). Recruitment was limited by the high prevalence of statin use in the screened population and a high prevalence of exclusions among hip fracture patients. CONCLUSION: Perioperative myocardial injury and inflammation are common in orthopedic patients and do not appear to be reduced in those randomized to atorvastatin. TRIAL REGISTRATION: NCT02197065.
BACKGROUND: Orthopedic patients are at risk for adverse postoperative cardiovascular outcomes. QUESTIONS/PURPOSES: This pilot randomized controlled trial (RCT) of atorvastatin vs. placebo in orthopedic surgery patients was performed in order to assess: (1) the prevalence of perioperative myocardial injury; (2) the effect of atorvastatin on perioperative inflammation; and (3) the feasibility of performing a large RCT of statin therapy in orthopedic patients. METHODS: Hip fracture (hip Fx) and total hip and knee replacement (THR and TKR) patients were randomized 1:1 to atorvastatin 40 mg daily vs. placebo, starting preoperatively and continuing until postoperative day (POD) 45. High-sensitivity cardiac troponin I (hs-cTnI), high-sensitivity C-reactive protein (hs-CRP), and interleukin-6 (IL-6) were measured preoperatively and on POD 2. Patients were monitored for adverse events until POD 90. RESULTS: Five hundred fifty-six patients were screened, 22 were recruited (4 hip Fx, 11 THR, 7 TKR), and 2 withdrew. Most (80%) had detectable hs-cTnI (> 1.1 pg/mL) preoperatively. Twenty percent had a perioperative rise in hs-cTnI (≥ 10 pg/mL), which was not blunted by atorvastatin. Hs-CRP rose in 19/20 patients, and IL-6 rose in all patients. However, atorvastatin did not blunt the rise in these inflammatory biomarkers. On POD 2, IL-6 and hs-cTnI levels correlated (ρ = 0.59, p = 0.02). Recruitment was limited by the high prevalence of statin use in the screened population and a high prevalence of exclusions among hip fracture patients. CONCLUSION: Perioperative myocardial injury and inflammation are common in orthopedic patients and do not appear to be reduced in those randomized to atorvastatin. TRIAL REGISTRATION: NCT02197065.
Authors: Anne Ruth Bass; Tomás Rodriguez; Gina Hyun; Francisco Gerardo Santiago; Jacqueline Ilji Kim; Scott Christopher Woller; Brian Foster Gage Journal: Int Orthop Date: 2015-07-09 Impact factor: 3.075
Authors: G L Bjornsson; L Thorsteinsson; K O Gudmundsson; H Jonsson; S Gudmundsson; B Gudbjornsson Journal: Scand J Immunol Date: 2007-01 Impact factor: 3.487
Authors: Goran Pesic; Jovana Jeremic; Tamara Nikolic; Vladimir Zivkovic; Ivan Srejovic; Aleksandra Vranic; Jovana Bradic; Branko Ristic; Aleksandar Matic; Nikola Prodanovic; Vladimir Jakovljevic Journal: Mol Cell Biochem Date: 2017-02-16 Impact factor: 3.396
Authors: Brandon S Oberweis; Nathaniel R Smilowitz; Swetha Nukala; Andrew Rosenberg; Jinfeng Xu; Steven Stuchin; Richard Iorio; Thomas Errico; Martha J Radford; Jeffrey S Berger Journal: Am J Cardiol Date: 2015-03-23 Impact factor: 2.778
Authors: Matthew A Cavender; William B White; Petr Jarolim; George L Bakris; William C Cushman; Stuart Kupfer; Qi Gao; Cyrus R Mehta; Faiez Zannad; Christopher P Cannon; David A Morrow Journal: Circulation Date: 2017-02-28 Impact factor: 29.690
Authors: Peter Nagele; Frank Brown; Brian F Gage; David W Gibson; J Philip Miller; Allan S Jaffe; Fred S Apple; Mitchell G Scott Journal: Am Heart J Date: 2013-06-24 Impact factor: 4.749
Authors: J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard Journal: N Engl J Med Date: 1995-11-16 Impact factor: 91.245
Authors: Hélène Vallet; Alice Breining; Yannick Le Manach; Judith Cohen-Bittan; Anthony Mézière; Mathieu Raux; Marc Verny; Bruno Riou; Frédéric Khiami; Jacques Boddaert Journal: Medicine (Baltimore) Date: 2017-02 Impact factor: 1.889
Authors: Alessandro Putzu; Carolina Maria Pinto Domingues de Carvalho E Silva; Juliano Pinheiro de Almeida; Alessandro Belletti; Tiziano Cassina; Giovanni Landoni; Ludhmila Abrahao Hajjar Journal: Ann Intensive Care Date: 2018-09-27 Impact factor: 6.925
Authors: Seth M Tarrant; Raymond G Kim; Jack M McDonogh; Matthew Clapham; Kerrin Palazzi; John Attia; Zsolt J Balogh Journal: J Clin Med Date: 2021-05-31 Impact factor: 4.241